Komori
Revision of earnings forecasts6568KNC Laboratories Co.,Ltd.Information and Communications, Services and Others

First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-Consolidated)

The full-year earnings forecast for the fiscal year ending March 2027 has been revised to net sales of ¥10,000 million, operating profit of ¥910 million, ordinary profit of ¥890 million and net income of ¥640 million. The company also provided forecasts of a year-end dividend of ¥17.00 per share and an annual dividend of ¥33.00 per share, but this document alone does not indicate whether the dividend has been increased or decreased.

Worth reading
66In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2027 · Full year
Net Sales—→10,000Millions of yen
—
Operating profit—→910Millions of yen
—
Ordinary income—→890Millions of yen
—
Profit attributable to owners of the parent—→640Millions of yen
—
Net income per share—→82.67yen and sen
—

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

Sales are expected to remain strong as the company steadily captures demand carried over from the previous fiscal year. However, upfront investments, including investment in human resources and depreciation associated with the operation of a new factory building, are expected to temporarily weigh on profits. The company also expects higher resource prices, personnel expenses due to an increase in headcount, and advertising and recruitment costs.

Details and amount of extraordinary loss

Loss on disposal of fixed assets: ¥0 thousand; total extraordinary losses: ¥0 thousand (cumulative first quarter)

Previous-period resultsNet Sales 9,093 Millions of yen / Operating profit 1,024 Millions of yen / Ordinary income 1,028 Millions of yen / Net income for the current fiscal year 766 Millions of yen
Dividend forecast revisionSecond-quarter-end dividend: ¥16.00; year-end dividend: ¥17.00; annual dividend: ¥33.00. The forecast has been revised from the most recently announced dividend forecast. For details, refer to the separate disclosure issued on 7 August 2026.
Consolidated / non-consolidatedNon-consolidated
Revised forecast
ItemDetails
Net SalesNot disclosed → 10,000 Millions of yen
Operating profitNot disclosed → 910 Millions of yen
Ordinary incomeNot disclosed → 890 Millions of yen
Profit attributable to owners of the parentNot disclosed → 640 Millions of yen
Net income per shareNot disclosed → 82.67 yen and sen
Fiscal Period CoveredFiscal year ending March 2027
Period CoveredFull year
Previous-period resultsNet Sales 9,093 Millions of yen / Operating profit 1,024 Millions of yen / Ordinary income 1,028 Millions of yen / Net income for the current fiscal year 766 Millions of yen
Reason for the revisionSales are expected to remain strong as the company steadily captures demand carried over from the previous fiscal year. However, upfront investments, including investment in human resources and depreciation associated with the operation of a new factory building, are expected to temporarily weigh on profits. The company also expects higher resource prices, personnel expenses due to an increase in headcount, and advertising and recruitment costs.
Details and amount of extraordinary lossLoss on disposal of fixed assets: ¥0 thousand; total extraordinary losses: ¥0 thousand (cumulative first quarter)
Dividend forecast revisionSecond-quarter-end dividend: ¥16.00; year-end dividend: ¥17.00; annual dividend: ¥33.00. The forecast has been revised from the most recently announced dividend forecast. For details, refer to the separate disclosure issued on 7 August 2026.
Consolidated / non-consolidatedNon-consolidated
Items this document does not state (1)
Publication date of previous forecast

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although sales are expected to remain strong as the company steadily captures demand carried over from the previous fiscal year, upfront investments for future growth, including investment in human resources and depreciation associated with the operation of a new factory building, are expected to temporarily weigh on profits. The company also expects higher resource prices, personnel expenses due to an increase in headcount, and advertising and recruitment costs.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Non-Consolidated) | KNC Laboratories Co.,Ltd. (6568) timely disclosure | Komori